{"id":11336,"date":"2024-08-14T08:56:58","date_gmt":"2024-08-14T08:56:58","guid":{"rendered":"https:\/\/www.friendly-bartik.94-130-216-58.plesk.page\/easthigh\/"},"modified":"2026-10-16T09:02:42","modified_gmt":"2026-10-16T09:02:42","slug":"easthigh","status":"publish","type":"page","link":"https:\/\/www.af-net.eu\/en\/easthigh\/","title":{"rendered":"EASThigh"},"content":{"rendered":"\n
\n
\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

EASThigh<\/strong>-AFNET 11<\/h2>\n\n\n\n
<\/div>\n\n\n\n

E<\/strong>arly atrial fibrillation A<\/strong>blation for ST<\/strong>roke prevention in patients with high<\/strong> comorbidity burden <\/p>\n<\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
\n
\n

Study design<\/strong><\/h2>\n\n\n\n
<\/div>\n\n\n\n

EASThigh-AFNET 11 is an international, prospective, randomized, open, blinded endpoint assessment, multicenter trial (Treatment Strategy trial).<\/p>\n\n\n\n

The objective of EASThigh-AFNET 11 is to investigate whether early atrial fibrillation ablation in patients with atrial fibrillation (AF) and a high comorbidity burden (CHA2DS2-VASc \u22654) reduces cardiovascular events (stroke, cardiovascular death, or heart failure events) compared to usual care.<\/p>\n<\/div>\n\n\n\n

\n
\n
<\/div>
<\/div>

You are currently viewing a placeholder content from YouTube<\/strong>. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.<\/p> More Information<\/a> <\/div>

Unblock content<\/a> Accept required service and unblock content<\/a> <\/div> <\/div> <\/div><\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
Inclusion Criteria<\/strong><\/h5>\n\n\n\n

\"\" AF first diagnosed within 5 years prior to enrolment and documented in body surface ECG<\/p>\n\n\n\n

\"\" High comorbidity estimated by CHA2DS2-VASc score of 4 or more<\/p>\n\n\n\n

\"\" Patient suitable for ablation using cryoballoon ablation systems or other ablation system with comparable efficacy and safety from Medtronic<\/p>\n\n\n\n

\"\" Age \u2265 18 years<\/p>\n\n\n\n

\"\" Provision of signed informed consent<\/p>\n<\/div>\n\n\n\n

\n
General exclusion criteria<\/strong><\/h5>\n\n\n\n

\"\" Any disease that limits life expectancy to less than 1 year.<\/p>\n\n\n\n

\"\" Participation in another clinical trial, either within the 3 months prior to enrolment or still on-going (participation in potential sub-studies connected to this trial is permitted).<\/p>\n\n\n\n

\"\"Previous participation in EASThigh-AFNET 11.<\/p>\n\n\n\n

\"\"Pregnant women.<\/p>\n\n\n\n

\"\"Breastfeeding women.<\/p>\n\n\n\n

\"\"Drug abuse or clinically manifest alcohol abuse.<\/p>\n<\/div>\n\n\n\n

\n
Exclusion criteria related to a cardiac condition<\/strong><\/h5>\n\n\n\n

\"\" Prior AF ablation or surgical therapy of AF.<\/p>\n\n\n\n

\"\" Patients not suitable for AF ablation.<\/p>\n\n\n\n

\"\"Patients with a history of stroke which occurred within 3 months prior to enrolment.<\/p>\n\n\n\n

\"\"Valve disease requiring specific therapy.<\/p>\n\n\n\n

\"\"Exclusion criteria based on laboratory abnormalities<\/p>\n<\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
\n

hypothesis<\/strong><\/strong><\/strong><\/h2>\n\n\n\n
<\/div>\n\n\n\n

The objective of EASThigh-AFNET 11 is to investigate whether early atrial fibrillation ablation in patients with atrial fibrillation (AF) and a high comorbidity burden reduces cardiovascular events compared to usual care.<\/p>\n<\/div>\n\n\n\n

\n

PATIENTS<\/strong><\/strong><\/strong><\/strong><\/p>\n\n\n\n

<\/span>%<\/span><\/div>
<\/div><\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
<\/div>\n\n\n\n
\n
<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n

<\/h2>\n\n\n\n

<\/p>\n<\/div>\n\n\n\n

\n

STUDY sites<\/strong><\/strong><\/p>\n\n\n\n

<\/span>%<\/span><\/div>
<\/div><\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n

International Recruitment status<\/strong><\/h2>\n\n\n\n
<\/div>\n\n\n\n
\"\"<\/figure>\n\n\n\n
<\/div>\n\n\n\n
\"\"<\/figure><\/div>\n\n\n\n
<\/div>\n\n\n\n

Study procedure<\/strong><\/h2>\n\n\n\n
<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
\n

Start of study<\/strong><\/strong><\/h4>\n\n\n\n

2024<\/strong><\/p>\n<\/div>\n\n\n\n

\n

Estimated end of study<\/strong><\/strong><\/h4>\n\n\n\n

endpoint-driven trial<\/strong><\/strong><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
\n

Study information for download<\/strong><\/h2>\n\n\n\n
<\/div>\n\n\n\n
\n
\n
\n\tStudy design<\/strong>
\n\t\t\"\"\n\t\t\"\"<\/a>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n
<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
\n

Publications<\/strong><\/h2>\n\n\n\n
<\/div>\n\n\n\n

Fabritz Larissa, Connolly D., Czarnecki E., Dudek D., Zlahoda-Huzior A., Guasch E., Haase D., Huebner T., Jolly K., Kirchhof P., Schotten Ulrich, Zapf Antonia, Schnabel Renate B: Remote Design of a Smartphone and Wearable Detected Atrial Arrhythmia in Older Adults Case Finding Study: Smart in OAC \u2013 AFNET 9<\/strong>. Frontiers in Cardiovascular Medicine, (2022), 9 https:\/\/www.frontiersin.org\/article\/10.3389\/fcvm.2022.839202<\/a><\/p>\n<\/div>\n<\/div>\n\n\n\n

\n

Coordinating Investigator<\/strong><\/h2>\n\n\n\n
<\/div>\n\n\n\n
\n
\n
\"\"<\/figure>\n<\/div>\n\n\n
Prof. Paulus Kirchhof<\/strong><\/h5>\n\n\n\n

Hamburg<\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/figure>\n<\/div>\n\n\n
PD Andreas Rillig<\/strong><\/h5>\n\n\n\n

Hamburg<\/p>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n
<\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
\n

More information<\/strong><\/h2>\n\n\n\n
<\/div>\n\n\n\n
\n
\n

Registration<\/h4>\n\n\n\n

ClinicalTrials.gov: NCT06324188<\/a><\/p>\n\n\n\n

support<\/h4>\n\n\n\n

British Heart Foundation<\/a><\/p>\n\n\n\n

Canadian Institutes of Health Research (ACT\/AEC)<\/a><\/p>\n\n\n\n

Dutch Heart Foundation<\/a><\/p>\n\n\n\n

Else Kr\u00f6ner Fresenius Stiftung<\/a><\/a><\/p>\n\n\n\n

Global Cardiovascular Research Funders Forum<\/a><\/p>\n\n\n\n

Medtronic<\/a><\/p>\n<\/div>\n\n\n\n

\n

Sponsor<\/h4>\n\n\n\n

Kompetenznetz Vorhofflimmern e.V. (Atrial Fibrillation NETwork, AFNET), M\u00fcnster, Germany<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

EASThigh-AFNET 11 Early atrial fibrillation Ablation for STroke prevention in patients with high comorbidity burden  Study design EASThigh-AFNET 11 is an international, prospective, randomized, open, blinded endpoint assessment, multicenter trial (Treatment Strategy trial). The objective of EASThigh-AFNET 11 is to investigate whether early atrial fibrillation ablation in patients with atrial fibrillation (AF) and a high comorbidity … Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_uag_custom_page_level_css":"","iawp_total_views":645,"_vp_format_video_url":"","_vp_image_focal_point":[],"footnotes":"","_members_access_role":[],"_members_access_error":""},"class_list":["post-11336","page","type-page","status-publish"],"acf":[],"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"timeline-express":false,"timeline-express-thumbnail":false,"1536x1536":false,"2048x2048":false,"vp_sm":false,"vp_md":false,"vp_lg":false,"vp_xl":false,"vp_sm_popup":false,"vp_md_popup":false,"vp_xl_popup":false},"uagb_author_info":{"display_name":"admin","author_link":"https:\/\/www.af-net.eu\/en\/author\/cre8ors\/"},"uagb_comment_info":0,"uagb_excerpt":"EASThigh-AFNET 11 Early atrial fibrillation Ablation for STroke prevention in patients with high comorbidity burden  Study design EASThigh-AFNET 11 is an international, prospective, randomized, open, blinded endpoint assessment, multicenter trial (Treatment Strategy trial). The objective of EASThigh-AFNET 11 is to investigate whether early atrial fibrillation ablation in patients with atrial fibrillation (AF) and a high comorbidity…","_links":{"self":[{"href":"https:\/\/www.af-net.eu\/en\/wp-json\/wp\/v2\/pages\/11336","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.af-net.eu\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.af-net.eu\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.af-net.eu\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.af-net.eu\/en\/wp-json\/wp\/v2\/comments?post=11336"}],"version-history":[{"count":40,"href":"https:\/\/www.af-net.eu\/en\/wp-json\/wp\/v2\/pages\/11336\/revisions"}],"predecessor-version":[{"id":18260,"href":"https:\/\/www.af-net.eu\/en\/wp-json\/wp\/v2\/pages\/11336\/revisions\/18260"}],"wp:attachment":[{"href":"https:\/\/www.af-net.eu\/en\/wp-json\/wp\/v2\/media?parent=11336"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}